HeartBeam Q2 Results: Net loss narrows to $5M, cash burn down 7%
HeartBeam Inc. posted a $5 million net loss for Q2 2026, with operating cash outflow falling 7% QoQ to $3.3 million. The firm holds $8.8 million in cash and has submitted an FDA pre-submission for heart attack detection. Commercial rollout in concierge practices is underway with first orders shipped.
*this image is generated using AI for illustrative purposes only.
HeartBeam Inc. (NASDAQ: BEAT) reported a net loss of $5 million for the second quarter ended June 30, 2026, as it advanced clinical trials and expanded its initial commercial launch. The company’s operating cash outflow declined 7% quarter-over-quarter to $3.3 million, reflecting tightened cost management and the completion of key product development phases.
The reported net loss included approximately $0.9 million in one-time items related to a leadership transition, comprising $0.6 million in non-cash stock-based compensation and $0.3 million in severance accruals. Excluding these items, the underlying net loss was approximately $4.1 million, representing a 12% decrease from the prior quarter.
Financial Highlights
| Metric | Q2 2026 | Change |
|---|---|---|
| Net Loss | $5 million | Includes $0.9M one-time items |
| Operating Cash Outflow | $3.3 million | Down 7% QoQ |
| Cash & Equivalents | $8.8 million | As of June 30, 2026 |
Cash, cash equivalents, and restricted cash totaled $8.8 million at the end of the quarter, following an April 2026 capital raise of $11.5 million. Management indicated that the reduced cost profile extends the cash runway into 2027. The company expects operating cash outflows to step down to below $2.5 million per quarter by Q4 2026, barring significant spending on a potential pivotal trial for myocardial infarction detection.
What the Numbers Show
The company’s ability to reduce operating cash outflows by 7% QoQ while simultaneously advancing multiple clinical studies and launching commercial operations suggests improved operational leverage. The completion of development for the credit-card-sized device and the prototype 12-lead patch removed significant capital expenditure burdens, allowing the firm to redirect resources toward clinical validation and early revenue generation without increasing overall burn.
Regulatory and Clinical Progress
HeartBeam submitted a pre-submission to the US Food and Drug Administration (FDA) for its heart attack detection indication. The company is pursuing a 510(k) regulatory pathway, aiming to commence a pivotal trial by year-end.
Key clinical milestones include:
- Completion of the ALIGN ACS pilot study enrollment in less than four months, involving 134 patients.
- Surpassing 50% enrollment in the Head Start ACS pilot study in Indonesia within three months.
- Initiation of a patch pilot study evaluating the device in approximately 50 patients.
Commercial Launch
The initial commercial launch is gaining momentum in concierge medicine practices across New York, Dallas, South Florida, and Southern California. First orders have shipped, with patient onboarding underway. Management noted positive feedback from physicians regarding the quality of the 12-lead EKG data provided by the pocket-sized device. The company estimates that reaching approximately 30,000 patients would be required to achieve break-even or cash-flow positivity, though current cost reductions may lower this threshold.
How might the potential initiation of a pivotal trial for myocardial infarction detection impact HeartBeam's projected cash runway into 2027?
What specific regulatory hurdles could delay the FDA's 510(k) clearance for the heart attack detection indication beyond the expected year-end timeline?
Can HeartBeam realistically lower its break-even threshold below 30,000 patients through further operational efficiencies or higher pricing power in concierge medicine?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
